Under the agreement, which spans over 18 months, the companies will analyse the genomes of patients to search for sequence variants to gain further insights into drug targets.
The research collaboration will utilize Decode’s comprehensive population genetics resources and analytical expertise and Pfizer’s genomic analysis for the discovery and development of drugs.
Decode founder and CEO Kari Stefansson said their research platform would help understand the genetic basis of disease and modifiers of clinical phenotypes in actual patient populations.